Department of Health and Social Care announces breast cancer radiotherapy trial milestone and new adviser

What was announced

The Department of Health and Social Care released details on several breast cancer measures on 30 October 2026. Over 1,000 people have joined the FAST-Forward Boost trial. Led by The Institute of Cancer Research, London, and funded by the National Institute for Health and Care Research, the study evaluates shortening radiotherapy from three weeks down to five days. The trial uses an extra targeted dose, called a boost, and aims to recruit 4,830 participants across 39 UK hospitals by 2028.

The department also announced that Ashley Dalton MP will advise on the National Cancer Plan. She stepped down as Parliamentary Under-Secretary of State for Public Health and Prevention in March 2026 to manage her metastatic breast cancer treatment. In her new role, she will work with Minister James Frith to evaluate cancer care delivery.

Additionally, government data shows first-time breast screening attendance reached 63.6 percent, the highest rate in ten years. The government is also testing artificial intelligence tools for mammogram analysis and partnering with Breast Cancer Now on patient support.

What it means

If the FAST-Forward Boost trial shows that five-day radiotherapy is safe, patients could cut their hospital visits by 10 trips. That would lower travel expenses, decrease time off work, and free up NHS capacity for other care.

The appointment of Ashley Dalton MP puts someone with direct personal experience of metastatic breast cancer into an advisory position. Her feedback will focus on identifying delays and assessing whether care policies match patient needs.

Screening uptake has risen, but four in 10 women invited for their first breast screening still miss their appointments. Finding cancer early improves outcomes. According to Breast Cancer Now, almost 100 percent of people diagnosed at stage 1 survive for five years or more, compared with 32 percent at stage 4.

What the announcement does not tell us

The announcement does not state when the artificial intelligence mammogram trials will complete or when the technology might be used across NHS hospitals. It also does not explain why around 40 percent of invited women miss their first screening appointment, nor does it outline specific measures to boost attendance beyond general encouragement. Finally, final results for the FAST-Forward Boost trial are not expected until 2033, so any permanent changes to standard NHS radiotherapy schedules will depend on data gathered years from now.